Richard Steinhart
Fortune : 83 510 $ au 31/05/2026
Fortune : 83 510 $ au 31/05/2026
Richard I.
Steinhart currently serves as Independent Director at Atossa Therapeutics, Inc. since 2014, Independent Director at Actinium Pharmaceuticals, Inc. since 2013, and Senior VP, Chief Financial & Accounting Officer at BioXcel Therapeutics, Inc. since 2017.
Former positions include Independent Director at TG Therapeutics, Inc. from 2011 to 2012; Managing Director at Forest Street Capital, LLC from 1992 to 2006; Managing Director at SAE Ventures; Chief Financial Officer & Vice President at Emisphere Technologies, Inc. from 1991 to 1992; CFO, Secretary, Treasurer & Senior VP-Finance at STRATA Skin Sciences, Inc. from 2012 to 2013; Chief Financial Officer & General Partner at CW Group, Inc. from 1991 to 1992; Chief Financial Officer & Vice President at Remedy Pharmaceuticals, Inc. from 2015 to 2017.
Education includes undergraduate and MBAistration degrees from Pace University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 12/05/2026 | 10 000 ( 0,12 % ) | 52 300 $ | 31/05/2026 | |
| 15/06/2026 | 26 335 ( 0,18 % ) | 30 812 $ | 31/05/2026 | |
| 15/10/2025 | 316 ( 0 % ) | 398 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| ACTINIUM PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 08/11/2013 |
| ATOSSA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 03/03/2014 |
| BIOXCEL THERAPEUTICS, INC. | Directeur Financier/CFO | 01/10/2017 |
| Sociétés | Poste | Fin |
|---|---|---|
Remedy Pharmaceuticals, Inc.
Remedy Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage pharmaceutical company that develops molecule drugs for acute central nervous system disorders | Directeur Financier/CFO | 01/04/2017 |
| STRATA SKIN SCIENCES, INC. | Directeur Financier/CFO | 31/12/2013 |
| TG THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/01/2012 |
Forest Street Capital, LLC | Corporate Officer/Principal | 24/04/2006 |
| EMISPHERE TECHNOLOGIES, INC. | Directeur Financier/CFO | 01/05/1992 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 11 |
|---|---|
Emisphere Technologies, Inc.
Emisphere Technologies, Inc. Pharmaceuticals: MajorHealth Technology Operates as a commercial stage pharmaceutical and drug delivery company | Health Technology |
TG Therapeutics, Inc.
TG Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
STRATA Skin Sciences, Inc.
STRATA Skin Sciences, Inc. Medical SpecialtiesHealth Technology Manufactures dermatology treatment products | Health Technology |
Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics and delivery methods for the treatment of breast cancer & other breast conditions | Health Technology |
CW Group, Inc.
CW Group, Inc. Investment ManagersFinance CW Group invests in companies located in the United States. The firm focuses on a broad range of sectors and industries. It provides financing for early stage capital requirements. | Finance |
Pace University
Pace University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Remedy Pharmaceuticals, Inc.
Remedy Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage pharmaceutical company that develops molecule drugs for acute central nervous system disorders | Health Technology |
Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers | Health Technology |
Forest Street Capital, LLC | |
SAE Ventures | |
BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops transformative medicines in neuroscience and immuno-oncology | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national